Iovance Biotherapeutics
IOVA
173 hedge funds and large institutions have $2.25B invested in Iovance Biotherapeutics in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 57 reducing their positions, and 23 closing their positions.
763% more call options, than puts
Call options by funds: $28.1M | Put options by funds: $3.26M
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
4% more funds holding
Funds holding: 167 → 173 (+6)
9% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 57
0.68% more ownership
Funds ownership: 99.01% → 99.69% (+0.68%)
25% less capital invested
Capital invested by funds: $3B → $2.25B (-$749M)
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45M |
| 2 |
State Street
Boston,
Massachusetts
|
+$29.6M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$26.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.8M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$14.5M |
Top Sellers
| 1 |
CCM
Consonance Capital Management
New York
|
-$92.3M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$39.2M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$37.6M |
| 4 |
PA
Perceptive Advisors
New York
|
-$19.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$10.8M |
IOVA Hedge Fund Activity: Q3 2019 in Review
173 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2019, worth a combined $2.25B — down 25% from $3B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IOVA positions and 23 closed out — a net gain of 6 holders — while 62 added to existing stakes and 57 trimmed.
The largest buyer was Vanguard Group, adding an estimated $45M. The largest seller was Consonance Capital Management, cutting an estimated $92.3M.
- 173 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2019, up from 167 in Q2 2019.
- Funds reported $2.25B of Iovance Biotherapeutics stock for Q3 2019, down 25% quarter-over-quarter.
- 29 funds opened new Iovance Biotherapeutics positions in Q3 2019 and 23 closed out, a net change of +6 holders.
- The largest Iovance Biotherapeutics buyer in Q3 2019 was Vanguard Group, an estimated $45M added.
- The largest Iovance Biotherapeutics seller in Q3 2019 was Consonance Capital Management, an estimated $92.3M sold.
Based on aggregated 13F filings for Q3 2019.